Albert Markus Kasel

Albert Markus Kasel

Auto-generated profile, based on publicly available information

Albert Markus Kasel

Department of Cardiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
AKAlbert M. Kasel
Albert M. Kasel
SCSalvatore Cassese
Salvatore Cassese
SBSabine Bleiziffer
Sabine Bleiziffer
MAMakoto Amaki
Makoto Amaki
RHRebecca T. Hahn
Rebecca T. Hahn
PSPartho P. Sengupta
Partho P. Sengupta

1 August 2017 in JACC
Verified
Journal Article
Closed access
SYSung-Han Yoon
Sung-Han Yoon
BWBrian K. Whisenant
Brian K. Whisenant
SBSabine Bleiziffer
Sabine Bleiziffer
VDVictoria Delgado
Victoria Delgado
NSNiklas Schofer
Niklas Schofer
RMRaj R. Makkar
Raj R. Makkar

1 February 2016 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
OHOliver Husser
Oliver Husser
CPCostanza Pellegrini
Costanza Pellegrini
TKThorsten Kessler
Thorsten Kessler
CBChristof Burgdorf
Christof Burgdorf
HTHannah Thaller
Hannah Thaller
CHChristian Hengstenberg
Christian Hengstenberg

2 February 1999 in Circulation
Verified
Journal Article
Closed access
PDF file
MGMartin Guethlin
Martin Guethlin
AKAlbert Markus Kasel
Albert Markus Kasel
KCKlaus Coppenrath
Klaus Coppenrath
SZSibylle Ziegler
Sibylle Ziegler
WDWolfram Delius
Wolfram Delius
MSMarkus Schwaiger
Markus Schwaiger
Background —Lipid-lowering therapy can improve endothelial function in patients with coronary artery disease (CAD) and hypercholesterolemia. Little is known about induced changes in myocardial microcirculation. This study prospectively investigated the temporal effects of lipid-lowering therapy with fluvastatin on coronary flow and flow reserve (CFR) in patients with CAD assessed by PET. Methods and Results —In an open clinical trial, CFR was studied in 15 patients with angiographically documented multivessel CAD and hypercholesterolemia (LDL >160 mg/dL). Dynamic 13 N-labeled ammonia PET imaging in conjunction with adenosine was used to assess regional and global CFR at baseline as well as at 2 and 6 months during treatment with fluvastatin (60 to 80 mg/d). Despite a rapid decrease in total cholesterol (29±6%) and LDL (37±9%), myocardial blood flow at rest and during stress was unchanged after 2 months of treatment (2.7±0.9 versus 2.5±0.6 mL · g −1 · min −1 ). At 6 months, stress blood flow as well as CFR increased significantly (3.4±1.0 mL · g −1 · min −1 ). No change in hemodynamic parameters was noted during the entire study. Nine of 15 patients increased CFR by >20%. All responders demonstrated improvement in anginal symptoms, whereas nonresponders stated no change (n=4) or worsening of symptoms (n=2). The improvement in CFR was not related to the amount of lipid lowering and was independent of the severity of stenoses. Conclusions —Improvement in stress blood flow and CFR is delayed compared with the lipid-lowering effect of fluvastatin, suggesting a slow recovery of the vasodilatory response to adenosine.

21 January 2022 in Investigative Radiology
Verified
Journal Article
Open access
VMVictor Mergen
Victor Mergen
TSThomas Sartoretti
Thomas Sartoretti
EKErnst Dipl Phys Klotz
Ernst Dipl Phys Klotz
BSBernhard Schmidt
Bernhard Schmidt
LJLisa Jungblut
Lisa Jungblut
Hatem AlkadhiHatem Alkadhi
Hatem Alkadhi
Objectives: The aim of this study was to evaluate the feasibility and accuracy of cardiac late enhancement (LE) scanning for extracellular volume (ECV) quantification with dual-source photon-counting detector computed tomography (PCD-CT). Materials and Methods: In this institutional review board–approved study, 30 patients (mean age, 79 years; 12 women; mean body mass index, 28 kg/m2) with severe aortic stenosis undergoing PCD-CT as part of their preprocedural workup for transcatheter aortic valve replacement were included. The scan protocol consisted of a nonenhanced calcium-scoring scan, coronary CT angiography (CTA) followed by CTA of the thoracoabdominal aorta, and a low-dose LE scan 5 minutes after the administration of 100 mL contrast media (all scans electrocardiogram-gated). Virtual monoenergetic (65 keV) and dual-energy (DE) iodine images were reconstructed from the LE scan. Extracellular volume was calculated using the iodine ratios of myocardium and blood-pool of the LE scan, and additionally based on single-energy (SE) subtraction of the nonenhanced scan from the LE scan. Three-dimensional analysis was performed automatically for the whole-heart myocardial volume by matching a heart model generated from the respective coronary CTA data. Bland-Altman and correlation analysis were used to compare the ECV values determined by both methods. Results: The median dose length product for the LE scan was 84 mGy·cm (interquartile range, 69; 125 mGy·cm). Extracellular volume quantification was feasible in all patients. The median ECV value was 30.5% (interquartile range, 28.4%–33.6%). Two focal ECV elevations matched known prior myocardial infarction. The DE- and SE-based ECV quantification correlated well (r = 0.87, P < 0.001). Bland-Altman analysis showed small mean errors between DE- and SE-based ECV quantification (0.9%; 95% confidence interval, 0.1%–1.6%) with narrow limits of agreement (−3.3% to 5.0%). Conclusions: Dual-source PCD-CT enables accurate ECV quantification using an LE cardiac DE scan at low radiation dose. Extracellular volume calculation from iodine ratios of the LE scan obviates the need for acquisition of a true nonenhanced scan and is not affected by potential misregistration between 2 separate scans.

1 October 2017 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
OHOliver Husser
Oliver Husser
WKWon-Keun Kim
Won-Keun Kim
CPCostanza Pellegrini
Costanza Pellegrini
AHAndreas Holzamer
Andreas Holzamer
TWThomas Walther
Thomas Walther
CHChristian Hengstenberg
Christian Hengstenberg